ESR1 and breast cancer: Compared to the non-Sjögren cohort, the Sjögren cohort had a significantly higher risk of breast cancer in terms of estrogen receptor positivity, especially at shorter follow-up times (180 days, 1 year) (HR: 3.627, 2.765, respectively).